NasdaqCM - Delayed Quote USD

HOOKIPA Pharma Inc. (HOOK)

0.8933 +0.0872 (+10.82%)
At close: April 26 at 4:00 PM EDT
0.8911 -0.00 (-0.25%)
After hours: April 26 at 7:59 PM EDT
Key Events
Loading Chart for HOOK
DELL
  • Previous Close 0.8061
  • Open 0.7950
  • Bid 0.8545 x 100
  • Ask 0.9132 x 100
  • Day's Range 0.7787 - 0.9489
  • 52 Week Range 0.4100 - 2.0500
  • Volume 2,863,483
  • Avg. Volume 778,266
  • Market Cap (intraday) 88.392M
  • Beta (5Y Monthly) 1.02
  • PE Ratio (TTM) --
  • EPS (TTM) -0.8600
  • Earnings Date May 9, 2024 - May 13, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 4.58

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial. The company's preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

www.hookipapharma.com

151

Full Time Employees

December 31

Fiscal Year Ends

Recent News: HOOK

Performance Overview: HOOK

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

HOOK
10.28%
S&P 500
6.92%

1-Year Return

HOOK
6.07%
S&P 500
25.26%

3-Year Return

HOOK
92.76%
S&P 500
22.00%

5-Year Return

HOOK
93.69%
S&P 500
74.29%

Compare To: HOOK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: HOOK

Valuation Measures

Annual
As of 4/26/2024
  • Market Cap

    88.39M

  • Enterprise Value

    -22.14M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.19

  • Price/Book (mrq)

    0.98

  • Enterprise Value/Revenue

    -1.10

  • Enterprise Value/EBITDA

    0.29

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -32.00%

  • Return on Equity (ttm)

    -84.81%

  • Revenue (ttm)

    20.13M

  • Net Income Avi to Common (ttm)

    -81.58M

  • Diluted EPS (ttm)

    -0.8600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    117.1M

  • Total Debt/Equity (mrq)

    7.30%

  • Levered Free Cash Flow (ttm)

    -39.97M

Research Analysis: HOOK

Analyst Price Targets

3.00
4.58 Average
0.8933 Current
6.50 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: HOOK

Fair Value

0.8933 Current
 

Dividend Score

0 Low
HOOK
Sector Avg.
100 High
 

Hiring Score

0 Low
HOOK
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
HOOK
Sector Avg.
100 High
 

People Also Watch